Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
NCT ID: NCT01385592
Last Updated: 2020-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
78 participants
INTERVENTIONAL
2011-11-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AFQ056 100 mg
AFQ056
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AFQ056
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Outpatients who are on a stable anti-parkinsonian treatment regimen for at least four weeks
Exclusion Criteria
* Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated)
* Advanced, severe or unstable disease (other than PD) or evidence of dementia that may interfere with the study outcome evaluations
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Sunnyvale, California, United States
Novartis Investigative Site
Englewood, Colorado, United States
Novartis Investigative Site
London, Ontario, Canada
Novartis Investigative Site
Gatineau, Quebec, Canada
Novartis Investigative Site
Clermont-Ferrand, , France
Novartis Investigative Site
Lille, , France
Novartis Investigative Site
Pessac, , France
Novartis Investigative Site
Poitiers, , France
Novartis Investigative Site
Beelitz-Heilstätten, , Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Bochum, , Germany
Novartis Investigative Site
Düsseldorf, , Germany
Novartis Investigative Site
Kassel, , Germany
Novartis Investigative Site
Leipzig, , Germany
Novartis Investigative Site
München, , Germany
Novartis Investigative Site
München, , Germany
Novartis Investigative Site
Stadtroda, , Germany
Novartis Investigative Site
Westerstede/Oldenburg, , Germany
Novartis Investigative Site
Budapest, , Hungary
Novartis Investigative Site
Kaposvár, , Hungary
Novartis Investigative Site
Szeged, , Hungary
Novartis Investigative Site
Bolzano, BZ, Italy
Novartis Investigative Site
Pisa, PI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Sant Cugat del Vallès, Barcelona, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Donostia / San Sebastian, , Spain
Novartis Investigative Site
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Trenkwalder C, Stocchi F, Poewe W, Dronamraju N, Kenney C, Shah A, von Raison F, Graf A. Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies. Mov Disord. 2016 Jul;31(7):1054-8. doi: 10.1002/mds.26585. Epub 2016 May 23.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CAFQ056A2222 from the Novartis Clinical Trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-002073-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CAFQ056A2222
Identifier Type: -
Identifier Source: org_study_id